Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF)

Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF)

Background: A regimen of dual (DAT) vs. triple (TAT) antithrombotic therapy reduces bleeding in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, recent evidence suggests that DAT may be associated with an increased ischemic risk. This raises the qu...

Full description

Bibliographic Details
Main Authors: Lisa Riesinger, Claudia Strobl, David M. Leistner, Tommaso Gori, Ibrahim Akin, Michael Mehr, Antonia Kellnar, Amir A. Mahabadi, Harilaos Bogossian, Michael Block, Frank Edelmann, Nikolaus Sarafoff, Dirk Sibbing, Hüseyin Ince, Tienush Rassaf, Ulrich Mansmann, Julinda Mehilli, Stefan Kääb, Jörg Hausleiter, Steffen Massberg, Reza Wakili
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:International Journal of Cardiology: Heart & Vasculature
Subjects:
Acute coronary syndrome
Atrial fibrillation
Apixaban
Antiplatelet therapy
Triple therapy
Anticoagulation
Online Access:http://www.sciencedirect.com/science/article/pii/S2352906721000981

Internet

http://www.sciencedirect.com/science/article/pii/S2352906721000981

Similar Items